SCHEMBL16641990

SCHEMBL16641990

Cc1ccc(NCc2cc(Cl)cc(Cl)c2O)c(C)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.57
SMN1; SMN2 Q16637 2/20 0.57
KMT2A Q03164 6/20 0.53
MEN1 O00255 5/20 0.53
LMNA P02545 3/20 0.53
HPGD P15428 2/20 0.53
POLB P06746 1/20 0.53
GAA P10253 2/20 0.49
ALB P02768 1/20 0.48
GFER P55789 2/20 0.47
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA9 Q16790 1/20 0.47
HIF1A Q16665 1/20 0.47
ALOX12 P18054 1/20 0.43
MCHR1 Q99705 1/20 0.42
PTGS2 P35354 1/20 0.42
HSP90AA1 P07900 1/20 0.41
PDE2A O00408 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16641985 0.90 KMT2A (0.54) MAPTSMN1; SMN2KMT2AMEN1LMNA
SCHEMBL12204318 0.86 KMT2A (0.51) MAPTSMN1; SMN2KMT2AMEN1LMNA
SCHEMBL16641992 0.84 KMT2A (0.58) MAPTSMN1; SMN2KMT2AMEN1LMNA
SCHEMBL16641986 0.81 CA1 (0.64) MAPTKMT2AMEN1LMNAHPGD
SCHEMBL12767424 0.80 MAPT (0.65) MAPTSMN1; SMN2KMT2AMEN1LMNA
SCHEMBL12767425 0.78 MAPT (0.51) MAPTSMN1; SMN2KMT2AMEN1LMNA
SCHEMBL16645384 0.77 CA1 (0.52) MAPTKMT2AMEN1LMNAHPGD
SCHEMBL16641984 0.75 ALB (0.61) MAPTSMN1; SMN2KMT2AMEN1LMNA
SCHEMBL11046759 0.75 HDAC1 (0.47) MAPTSMN1; SMN2KMT2AMEN1LMNA
SCHEMBL13987052 0.73 MAPT (1.00) MAPTSMN1; SMN2KMT2AMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150105324-A1 COMPOSITIONS AND METHODS FOR TREATING PTSD AND RELATED DISEASES INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION 2015-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150105324-A1 COMPOSITIONS AND METHODS FOR TREATING PTSD AND RELATED DISEASES GRIN2A, GRIN1, GRIN2C MAPT 813/4885SMN1; SMN2 850/4885KMT2A 1058/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.